19 active not recruiting, 18 recruiting, 14 completed, 7 unknown. 45 Phase 2, 24 Phase 1, 6 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow zimberelimab: new trials by email Literature Review of zimberelimab trials Research Report on zimberelimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Futibatinib, Zimberelimab, Durvalumab - Biliary Tract Cancer | Phase 3 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 784 | 2026-06-24 | 2026-07-17 |
| A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer Becotatug Vedotin in combination with Zimberelimab - Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 30 | 2026-06-11 | 2026-06-16 |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC Zimberelimab (AB122), Domvanalimab (DOM), Sacituzumab Govitecan (SG) - Triple Negative Breast Cancer, PDL-1 Positive | Phase 2 | Withdrawn | MedSIR | 2026-04-01 | 2026-05-01 | |
| Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) FOLFIRI + Zimberelimab + Domvanalimab, FOLFIRI (standard of care) - Carcinoma, Neuroendocrine | Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 122 | 2026-04-01 | 2026-01-13 |
| Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC Casdatifan, Zimberelimab - Renal Cell Carcinoma, Kidney Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2026-03-09 | 2026-03-20 |
| Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma Zimberelimab, Domvanalimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) - Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-02-01 | 2025-12-26 | |
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 Domvanalimab, Zimberelimab, Paclitaxel - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Gilead Sciences | 39 | 2025-02-18 | 2026-09-03 |
| Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. Zimberelimab, Sacituzumab govitecan, Cisplatin - Lung Diseases, Carcinoma, Non-Small-Cell Lung | Phase 3 | Recruiting | Fundación GECP | 129 | 2025-02-04 | 2026-05-18 |
| PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer Sacituzumab govitecan, Zimberelimab, Domvanalimab - Urothelial Bladder Carcinoma | Phase 2 | Active not recruiting | Fundación para el Progreso de la Oncología en Cantabria | 70 | 2025-01-20 | 2026-10-07 |
| A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies COM503, Zimberelimab - Neoplasm, Cancer, Malignant Tumors | Phase 1 | Recruiting | Compugen Ltd | 200 | 2025-01-07 | 2026-08-12 |
| Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan - Breast Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 31 | 2024-12-19 | 2025-12-05 |
| Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer Sacituzumab Govitecan + Zimberelimab - Bladder Cancer, Bladder Urothelial Carcinoma | Phase 2 | Not yet recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 63 | 2024-12-02 | 2024-07-30 |
| Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors GS-2121, Zimberelimab - Advanced Solid Tumors | Phase 1 | Recruiting | Gilead Sciences | 154 | 2024-07-26 | 2026-04-21 |
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Gulam Manji | 60 | 2024-05-10 | 2026-02-27 |
| Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) Gemcitabine, Cisplatin, Zimberelimab - Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Active not recruiting | Nataliya Uboha | 33 | 2024-03-08 | 2026-08-17 |
| A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer Disitamab Vedotin, Zimberelimab - Cervical Cancer | Phase 2 | Recruiting | RemeGen Co., Ltd. | 116 | 2024-01-11 | 2024-02-28 |
| Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer Zimberelimab, Oxaliplatin, S-1 - Previously AG Chemotherapy Treated Pancreatic Cancer | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 19 | 2024-01-01 | 2023-12-12 |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers Zimberelimab, Etrumadenant, Cisplatin - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Withdrawn | Jennifer Choe | 2023-12-31 | 2023-11-30 |
Showing 20 of 70. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (10) · Uterine Cervical Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (6) · Stomach Neoplasms (5) · Carcinoma, Renal Cell (4) · Pancreatic Neoplasms (4) · Recurrence (4) · Triple Negative Breast Neoplasms (4) · Cholangiocarcinoma (3) · Lung Neoplasms (3) · Melanoma (3) · Urinary Bladder Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Breast Neoplasms (2) · Colorectal Neoplasms (2)
Arcus Biosciences, Inc. (14) · Gilead Sciences (11) · Guangzhou Gloria Biosciences Co., Ltd. (6) · Sun Yat-sen University (3) · Hospices Civils de Lyon (2) · Jonsson Comprehensive Cancer Center (2) · Catherine Spina (1) · Coherus Oncology, Inc. (1) · Compugen Ltd (1) · Dana-Farber Cancer Institute (1) · Diwakar Davar (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fudan University (1) · Fundación GECP (1) · Fundación para el Progreso de la Oncología en Cantabria (1)
United States (43) · China (18) · South Korea (13) · Spain (13) · Australia (12) · Canada (10) · France (10) · Taiwan (10) · United Kingdom (9) · Italy (8) · Hong Kong (6) · Turkey (Türkiye) (5) · Israel (4) · Poland (4) · Brazil (3)
Catherine S. Spina, MD, PhD (1) · Daniel Morgensztern, M.D. (1) · David Hsieh, MD (1) · Diwakar Davar, MD (1) · Encouse Golden, M.D., Ph.D. (1) · Giuseppe Procopio, MD (1) · Guiling Li, Doctor (1) · Gulam Manji, MD, PhD (1) · Hongxi Zhao, PhD (1) · Ignacio Duran, MD (1) · James Cleary, MD, PhD (1) · Jennifer Choe, MD, PhD (1) · Jianmin Fang, Ph.D (1)
PMID 33691262, PMID 33929895, PMID 34462189, PMID 37875323, PMID 38261969, PMID 38682560, PMID 39186707, PMID 39799811, PMID 40341124, PMID 40592848, PMID 41109921, PMID 41912809, PMID 42481461
2023 (3), 2025 (1), R01CA266757 (1)